Tirzepatide has been extensively studied in clinical settings for its role in supporting physician-guided weight loss and metabolic health
Discussion Recent publications of positive CV outcome trials with SGLT2i (empagliflozin and canagliflozin) and GLP1 RA (liraglutide and semaglutide) and the positive effects of treatment with these drugs utilizing the pathophysiological defects of T2D have caused a paradigm shift in the way the disease is treated [1,2,3,4]
Compared with SGLT2 inhibitors (such as dapagliflozin or empagliflozin), both classes offer cardiovascular benefits, low hypoglycaemia risk, and weight loss
Tang J, Zhu J, Xie H, Song L, Xu G, Li W, et al
Experts agree that a diet high in processed foods is not healthy